Charles Schwab Investment Management Inc. Grows Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)

Charles Schwab Investment Management Inc. lifted its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 2.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,161,352 shares of the medical research company’s stock after purchasing an additional 26,701 shares during the period. Charles Schwab Investment Management Inc. owned about 0.90% of NeoGenomics worth $19,139,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new position in NeoGenomics in the fourth quarter valued at $26,000. Versant Capital Management Inc boosted its holdings in NeoGenomics by 174.9% in the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 1,142 shares during the period. Quarry LP purchased a new position in NeoGenomics in the third quarter valued at $40,000. Smartleaf Asset Management LLC boosted its holdings in NeoGenomics by 203.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 2,787 shares during the period. Finally, Blue Trust Inc. raised its stake in NeoGenomics by 33.2% in the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company’s stock valued at $73,000 after buying an additional 1,103 shares in the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

NeoGenomics Stock Up 3.5 %

NEO opened at $9.95 on Thursday. The business’s 50-day simple moving average is $12.61 and its 200-day simple moving average is $14.66. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. NeoGenomics, Inc. has a one year low of $8.98 and a one year high of $19.12. The stock has a market capitalization of $1.28 billion, a P/E ratio of -16.05 and a beta of 1.28.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The firm had revenue of $172.00 million for the quarter, compared to analyst estimates of $173.40 million. Analysts anticipate that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on NEO shares. Bank of America cut their price target on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. Jefferies Financial Group started coverage on NeoGenomics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target on the stock. Piper Sandler cut their price target on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group cut their price target on NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Finally, Needham & Company LLC cut their price target on NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.60.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.